Despite the recent availability of vaccines against severe acute respiratory syndrome
coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 …

Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to
emerge and spread around the world, antibodies and vaccines to confer broad and potent …

The COVID-19 pandemic represents a global challenge that has impacted and is expected
to continue to impact the lives and health of people across the world for the foreseeable …

The COVID-19 pandemic is a major threat to global health for which there are only limited
medical countermeasures, and we lack a thorough understanding of mechanisms of …

Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Effective therapies are urgently needed for the SARS-CoV-2/COVID19 pandemic. We
identified panels of fully human monoclonal antibodies (mAbs) from eight large …

Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …